Maryvonne Hourmant

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

Jacques Dantal, Maryvonne Hourmant, Diego Cantarovich et al. · The Lancet · 1998 · 747 citations

Medicine, Immunology, Oncology +15

Type of PKD1 Mutation Influences Renal Outcome in ADPKD

Émilie Cornec-Le Gall, Marie‐Pierre Audrézet, Jian‐Min Chen et al. · Journal of the American Society of Nephrology · 2013 · 508 citations · Full text

Medicine, Genetics, Nephrology +14

Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients

Nassim Kamar, Jacques Izopet, Simona Tripon et al. · New England Journal of Medicine · 2014 · 507 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Christoph Licht, Larry A. Greenbaum, Petra Muus et al. · Kidney International · 2015 · 415 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +17